Searching…
Bevacizumab maintenance therapy significantly reduces progression and improves survival in advanced non-small cell lung cancer patients after induction therapy.
Dec 14, 2006 · Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers. Between July 2001 and April 2004, the Eastern Cooperativ...
Other Study ID Numbers NCI-2012-02947 E4599 U10CA021115 ( U.S. NIH Grant/Contract ) CDR0000068744 ( Registry Identifier ) (REGISTRY: PDQ (Physician Data Query))
Nov 22, 2013 · 该研究表明中国患者的无进展生存期（PFS）获益与先前的关键研究E4599结果一致，即相较于单纯接受化疗的患者，接受以安维汀 ® 为基础的一线治疗的患者无疾病进展生存期显著延长。 BEYOND是首个专门针对安维汀 ® 在中国非小细胞肺癌患者人群疗效的临床研究。
Jun 20, 2006 · Background: E4599 compared carboplatin and paclitaxel (PC) versus carboplatin, paclitaxel, and bevacizumab (PCB) in patients with advanced stage non-small cell lung cancer. Survival was superior with PC...
May 21, 2020 · 在靶向治疗问世以前，晚期NSCLC的预后较差，这一联合治疗策略在晚期非鳞NSCLC方面的探索具有里程碑式的意义，其中代表性的研究为E4599研究，这是首个证实贝伐珠单抗+化疗一线治疗非鳞NSCLC，可以让患者的总生存时间（OS）超过1年的Ⅲ期临床研究。
The limitations of this analysis are its retrospective nature and that E4599 was not designed to address the role of maintenance bevacizumab in this setting. The primary objective of ECOG 4599 was to evaluate the effi...
Oct 2, 2024 · These initial results prompted the confirmatory phase III study, E4599, comparing CP with or without BV in individuals with nonsquamous NSCLC October 2, 2024 by Julie Perry
Jun 21, 2024 · 为了进一步探究这一联合治疗方案在不同组织学分类下的疗效和安全性，研究者们进行了东部合作组E4599研究，并在此对基于肿瘤组织学分类的治疗结果进行详细分析。 通过对东部合作组E4599研究的数据进行深入分析，研…
In the open-label E4599trial, median overall survival duration was significantly extended by 2 months and median progression-free survival was significantly increased by 1.7 months when intravenous bevacizumab 15 mg/k...
